- Next Science Limited is an emerging medical technology company, established in 2012, headquartered in Australia.
- Next Science is commercialising its unique XbioTM technology platform through products that provide a non-toxictreatment for biofilm based infections.
- Biofilms pose a far-reaching threat to humans, animals and the environment, representing 90% of all bacteria.
- Bacteria protected by a biofilm can be 1,000x more resistant to antibiotics than free floating bacteria.
- Over 70,000 patients have been treated with Xbio technology in the US market to date.
- Next Science has 4 FDA cleared products currently in the US market to treat and manage surgical site infectionsand chronic wounds, and expects to have 8 products in market by the end of 2019 .
- Distribution agreements with major multinationals validate the Company’s Xbio technology .
- Next Science has a rapid growth trajectory with an extensive pipeline of products in both medical devices, OTCproducts and pharmaceutical applications
- Unique, non-toxic platform technology with proven efficacy in eradicating biofilm andbacteria.
- Addresses a clear unmet medical need and avoids creating antibacterial resistance
- Commercial demand proven by early sales agreements with global industry leaders . Zimmer Biomet (global leader in joint replacements) for Bactisure surgical lavage (wash) 3M (a global leader in wound care) for BlastX wound gel
- Multiple products targeting high value market segments with unmet needs
- 8 products expected to be in market by end 2019
- Extensive product pipeline across medical devices, OTC drugs and prescriptionpharmaceuticals
- High margin and highly scalable production, with contract manufacturing in 4 countries
- Broad international IP protection with 15 granted patents and 47 applications pending
- Rapid sales growth through leveraging global distribution partners, launching new productsinto new markets, and via geographic expansion, with 8 products in market by end 2019
- Next Science expects to benefit from multiple compounding growth drivers in 2019 and beyond:
- Increased market penetration of existing products in the US market
- Geographic expansion of sales outside the US- with entry to Australia and Europe expected in 2019
- Development and commercialisation of new products and applications in human health
- Next Science expects to have 8 products in market by end 2019, up from 2 in early 2018
- Extension of Xbio technology into applications outside human health .
- Manufacturing and production is highly scalable, using FDA or CE Mark audited contract manufacturers in theUSA, Europe, Australia and Mexico
- Circa 500% revenue growth to A$20m in 2019 implied in management performance hurdles under the LTI plan
It should do extremely well in short and medium term IMO and a potential multibagger for long term.
It was very hard to get any stock in the IPO . Managed to get a tiny allocation in IPO .
DYOR
ALL IMO
GLTAH
- Forums
- ASX - By Stock
- IPO - Next Science Limited
Next Science Limited is an emerging medical technology company,...
-
- There are more pages in this discussion • 208 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NXS (ASX) to my watchlist
(20min delay)
|
|||||
Last
32.5¢ |
Change
-0.010(2.99%) |
Mkt cap ! $94.80M |
Open | High | Low | Value | Volume |
34.5¢ | 34.5¢ | 31.5¢ | $32.36K | 96.42K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 16254 | 32.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
32.5¢ | 29495 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 16254 | 0.320 |
2 | 10777 | 0.315 |
1 | 14000 | 0.305 |
3 | 45000 | 0.300 |
1 | 3448 | 0.290 |
Price($) | Vol. | No. |
---|---|---|
0.325 | 29495 | 1 |
0.330 | 116 | 3 |
0.335 | 19012 | 1 |
0.340 | 7000 | 1 |
0.360 | 5000 | 1 |
Last trade - 16.10pm 28/03/2024 (20 minute delay) ? |
|
|||||
Last
32.5¢ |
  |
Change
-0.010 ( 3.68 %) |
|||
Open | High | Low | Volume | ||
35.3¢ | 35.3¢ | 32.0¢ | 61830 | ||
Last updated 15.59pm 28/03/2024 ? |
Featured News
NXS (ASX) Chart |
The Watchlist
BGD
BARTON GOLD HOLDINGS LIMITED
Alex Scanlon, Managing Director & CEO
Alex Scanlon
Managing Director & CEO
SPONSORED BY The Market Online